These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 23487171)

  • 1. Beyond LDL cholesterol in assessing cardiovascular risk: apo B or LDL-P?
    Master SR; Rader DJ
    Clin Chem; 2013 May; 59(5):723-5. PubMed ID: 23487171
    [No Abstract]   [Full Text] [Related]  

  • 2. In reply.
    Cole TG; Contois JH; Csako G; McConnell JP; Remaley AT; Devaraj S; Hoefner DM; Mallory T; Sethi AA; Warnick GR
    Clin Chem; 2013 Aug; 59(8):1277-8. PubMed ID: 24049794
    [No Abstract]   [Full Text] [Related]  

  • 3. Apolipoprotein B and nuclear magnetic resonance particle number.
    Stern RH
    Clin Chem; 2013 Aug; 59(8):1276-7. PubMed ID: 23759731
    [No Abstract]   [Full Text] [Related]  

  • 4. Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices.
    ; Cole TG; Contois JH; Csako G; McConnell JP; Remaley AT; Devaraj S; Hoefner DM; Mallory T; Sethi AA; Warnick GR
    Clin Chem; 2013 May; 59(5):752-70. PubMed ID: 23386699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of assessment techniques: plasma lipid and lipoproteins related to the metabolic syndrome.
    Davy BM; Davy KP
    Lipids Health Dis; 2006 Jan; 5():3. PubMed ID: 16448573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association of apolipoprotein B and low density lipoprotein with cardiovascular risk factors in the Thai population.
    Krittayaphong R; Chotinaiwatarakul C; Kangkagate C; Bhuripanyo K; Mahanonda N
    J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S1-7. PubMed ID: 17722296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Semiologic value of LDL cholesterol and apolipoprotein B in risk of atherosclerosis].
    Frey J; Couderc R
    Ann Biol Clin (Paris); 1998; 56(5):517-20. PubMed ID: 9769517
    [No Abstract]   [Full Text] [Related]  

  • 8. LDL cholesterol. New measurements of risk.
    Mayo Clin Health Lett; 2011 May; 29(5):1-3. PubMed ID: 21656931
    [No Abstract]   [Full Text] [Related]  

  • 9. [The cholesterol contained in low-density lipoproteins or apolipoprotein B in the prediction of cardiovascular risk?].
    Vella Ramírez JC
    Rev Sanid Hig Publica (Madr); 1992; 66(5-6):251-5. PubMed ID: 1366222
    [No Abstract]   [Full Text] [Related]  

  • 10. [Apolipoprotein B and LDL cholesterol: which parameter(s) should be included in the assessment of cardiovascular risk?].
    Bloch S; Couderc R
    Ann Biol Clin (Paris); 1998; 56(5):539-44. PubMed ID: 9769484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triglycerides and small dense LDL: the twin Achilles heels of the Friedewald formula.
    Sniderman AD; Blank D; Zakarian R; Bergeron J; Frohlich J
    Clin Biochem; 2003 Oct; 36(7):499-504. PubMed ID: 14563441
    [No Abstract]   [Full Text] [Related]  

  • 12. [Determination of apolipoproteins: An important tool for prevention and treatment of cardiovascular diseases].
    Wiklund O
    Lakartidningen; 2007 May 14-29; 104(20-21):1623-4. PubMed ID: 17564272
    [No Abstract]   [Full Text] [Related]  

  • 13. Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoproteins B and A-I--new risk factors and targets for therapy.
    Walldius G; Jungner I
    Nutr Metab Cardiovasc Dis; 2007 Oct; 17(8):565-71. PubMed ID: 17631989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apolipoprotein B, non-HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk.
    Holewijn S; den Heijer M; Swinkels DW; Stalenhoef AF; de Graaf J
    J Intern Med; 2010 Dec; 268(6):567-77. PubMed ID: 21091808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of propranolol on the plasma lipoprotein levels with special reference to apolipoproteins B].
    Banasiak W; Telichowski C; Molenda W; Majda J; Petruk J
    Pol Tyg Lek; 1986 Sep; 41(38):1203-5. PubMed ID: 3822884
    [No Abstract]   [Full Text] [Related]  

  • 16. Introduction: Apolipoproteins and guidelines for prevention of cardiovascular disease.
    Faergeman O
    J Intern Med; 2006 May; 259(5):434-6. PubMed ID: 16629848
    [No Abstract]   [Full Text] [Related]  

  • 17. Alcohol consumption and its relation to lipid-based cardiovascular risk factors among middle-aged women: the role of HDL(3) cholesterol.
    Sillanaukee P; Koivula T; Jokela H; Pitkäjärvi T; Seppä K
    Atherosclerosis; 2000 Oct; 152(2):503-10. PubMed ID: 10998480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ApoB/apoA-I ratio is better than LDL-C in detecting cardiovascular risk.
    Carnevale Schianca GP; Pedrazzoli R; Onolfo S; Colli E; Cornetti E; Bergamasco L; Fra GP; Bartoli E
    Nutr Metab Cardiovasc Dis; 2011 Jun; 21(6):406-11. PubMed ID: 20171854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meet LDL's partner in plaque. ApoB puts the "bad" in bad cholesterol.
    Gebel E
    Diabetes Forecast; 2008 May; 61(5):39-40. PubMed ID: 18499924
    [No Abstract]   [Full Text] [Related]  

  • 20. Relationship of apolipoprotein B levels to the number of risk factors for metabolic syndrome.
    Clarenbach JJ; Grundy SM; Palacio N; Vega GL
    J Investig Med; 2007 Jul; 55(5):237-47. PubMed ID: 17850735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.